• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Regeneron (REGN) Stock Price Faces Margin Squeeze Despite 17% Revenue Growth

    Simply Wall St·08/01/2026 06:39:01
    Listen to the news

    Regeneron Pharmaceuticals stock jumped about 3% to around US$763 after its latest report, a clear sign traders liked what they saw in the headline numbers. The bigger story sits in the profit engine behind that move. Quarterly basic earnings per share came in at US$12.62 on revenue of US$4.29b, while trailing net margin stands at 27.9%, compared with 31.4% a year earlier. In the short term, the market is cheering the earnings print. Over a longer horizon, investors now have to weigh that margin squeeze against the company’s drug portfolio and valuation profile.

    Is Regeneron Pharmaceuticals trading at a genuine discount, or does the sharp gap between its current US$762.63 share price and the DCF estimate hint at a value trap instead? Compare that story with the valuation analysis for Regeneron Pharmaceuticals

    Q2 2026 Earnings Summary

    • Revenue, Q2 2026 vs. Q2 2025: US$4,290.7m vs. US$3,675.6m (up about 17%)
    • Net Income, Q2 2026 vs. Q2 2025: US$1,296.9m vs. US$1,391.6m (down about 7%)
    • Basic EPS, Q2 2026 vs. Q2 2025: US$12.62 vs. US$13.24 (down about 5%)
    • Pipeline Depth, Q2 2026 vs. Q2 2025: 30 products in Phase II, 23 in Phase III and 6 in pre registration vs. 30 in Phase II, 22 in Phase III and 8 in pre registration (slight mix shift with a small step up in late stage trials)

    Prefer clear visuals over scrolling through pages of earnings tables and margin figures? See how Regeneron Pharmaceuticals looks in one clean view, including a valuation snapshot that sits alongside key financial drivers, with the full company report for Regeneron Pharmaceuticals.

    NasdaqGS:REGN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    NasdaqGS:REGN Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Evaluating Regeneron’s Growth-Milestone Story

    The bullish story on Regeneron Pharmaceuticals is that Dupixent, EYLEA HD and oncology assets can support a broader, more resilient growth engine as capacity investments kick in. Q2 results give that claim some backing. Revenue rose 17% year on year, yet net income and basic EPS both slipped, so the top line is moving faster than profits. That fits a company leaning into R&D and business development rather than one simply harvesting margins.

    On the commercial side, Dupixent, EYLEA HD and Libtayo each set quarterly sales records, which directly supports the idea that the core franchises are still gaining share and absorbing biosimilar and payer pressure. The pipeline depth is intact as well, with a small step up in Phase III programs and a roughly 3% post earnings share price move suggesting investors recognised those operational milestones as meaningful progress rather than just a one quarter blip.

    Reveal where the surface looks calm but the models quietly shift for Regeneron Pharmaceuticals, including when revenue and EPS curves start to pull away from today’s US$762.63 share price, by accessing the analyst estimates for Regeneron Pharmaceuticals.

    Regeneron Bear Case: Mixed Evidence On Concentration And Margins

    The bearish view on Regeneron Pharmaceuticals centers on heavy dependence on a few blockbusters, worsening erosion in ophthalmology, pipeline missteps after fianlimab and sustained margin pressure from rising R&D. Q2 data only partially supports that script. Dupixent, EYLEA HD and Libtayo each posted record quarters, and EYLEA HD now makes up about 60% of the U.S. aflibercept franchise. That directly counters fears of uncontrolled EYLEA biosimilar erosion, at least for now. At the same time, revenue rose 17% while net income and basic EPS both fell, and trailing net margin compressed from 31.4% to 27.9%. That is consistent with bears’ margin worries, especially given the IPR&D charge and heavier pipeline spend. The fianlimab setback and new securities class action keep execution and legal risk firmly on the table. The 3.3% share price move suggests investors saw progress, but not a full dismissal of the risk story.

    With five year EPS trending down and margins already under pressure, investors in Regeneron Pharmaceuticals cannot ignore balance sheet strength and cash flexibility. Verify how resilient that cushion really is in our financial health analysis of Regeneron Pharmaceuticals stock.

    Stay Ahead Of Your Next Move

    If Regeneron Pharmaceuticals' mix of revenue growth and margin pressure has your attention, register for free with Simply Wall St and add it to a Watchlist to track its share price against fair value and watch for an entry point that fits your plan. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the earnings, margin and balance sheet updates that matter most. For a longer term view, tap into the Community to see how other investors are thinking about the same risks and catalysts. This combination helps you surface hidden drivers early and stay ahead of market moves on Regeneron Pharmaceuticals and the rest of your watchlist.

    Seeking Alternatives Beyond Regeneron Pharmaceuticals?

    Fresh ideas can move quickly. Some stocks are already building breakout momentum while they are still under the radar for now. Scan these curated shortlists before the best entry points are gone and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.